Methionine Aminopeptidase 2 (Metap2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Methionine Aminopeptidase 2 (Metap2) Inhibitor The ...
January 2022
60 pages
mGlu 2/3 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “mGlu 2/3 Agonist The report assesses the active mGlu 2/3 Agonist ...
January 2022
60 pages
mGlu 2/3/5 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “mGlu 2/3/5 Antagonist The report assesses ...
January 2022
60 pages
mGlu5 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “mGlu5 Antagonist The report assesses the active mGlu5 Antagonist ...
January 2022
60 pages
Mitochondrial Electron Transport Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Mitochondrial Electron Transport Inhibitor The report ...
January 2022
60 pages
Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... , product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitor The ...
January 2022
60 pages
Monoamine Oxidase Inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Monoamine Oxidase Inhibitor (MAOIs) The report ...
January 2022
60 pages
Monoamine Oxidase B (MAO-B) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Monoamine Oxidase B (MAO-B) Inhibitor The report ...
January 2022
60 pages
mTORC-1 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “mTORC-1 Inhibitor The report assesses the active mTORC-1 Inhibitor ...
January 2022
60 pages
mTORC-2 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “mTORC-2 Inhibitor The report assesses the active mTORC-2 Inhibitor ...
January 2022
60 pages
Mu Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Mu Antagonist The report assesses the active Mu Antagonist pipeline ...
January 2022
60 pages
Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Murine Double Minute 2 (MDM2) Inhibitor The report ...
January 2022
60 pages
Muscarinic Acetylcholine Receptor (mAChR) Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Muscarinic Acetylcholine Receptor (mAChR) Antagonist The ...
January 2022
90 pages
Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Muscarinic Acetylcholine Receptor M2 Antagonist The ...
January 2022
60 pages
Muscarinic Acetylcholine Receptor M3 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Muscarinic Acetylcholine Receptor M3 Antagonist The ...
January 2022
60 pages
Muscarinic Agonist - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Muscarinic Agonist ...
January 2022
60 pages
Muscarinic M1 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Muscarinic M1 Agonist The report assesses ...
January 2022
60 pages
Myostatin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Myostatin Inhibitor The report assesses ...
January 2022
60 pages
Neurokinin (NK) Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Neurokinin (NK) Receptor Antagonist The report ...
January 2022
60 pages
Neurokinin 1 (NK1) Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Neurokinin 1 (NK1) Receptor Agonist The report ...
January 2022
60 pages
Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor ...
January 2022
60 pages
Neutrophil Elastase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Neutrophil Elastase Inhibitor The report assesses ...
January 2022
60 pages
NMDA Receptor Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “NMDA Receptor Antagonist The report assesses ...
January 2022
120 pages
Non Selective COX Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Non Selective COX Inhibitor The report assesses ...
January 2022
60 pages
Non-Receptor Tyrosine Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Non-Receptor Tyrosine Kinase Inhibitor The report ...
January 2022
60 pages
Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Non-Structural Protein 5 Inhibitor The report ...
January 2022
90 pages
Notch Signaling Pathway Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Notch Signaling Pathway Inhibitor The report ...
January 2022
90 pages
Nrf2 Pathway Activators - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Nrf2 Pathway Activators The report assesses the active Nrf2 Pathway ...
January 2022
60 pages
Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s The ...
January 2022
60 pages
Opioid Receptor Agonists - Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Opioid Receptor Agonist The report assesses ...
January 2022
90 pages
Orexin Receptor (Hypocretin Receptor) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Orexin Receptor (Hypocretin Receptor) Antagonist The ...
January 2022
60 pages
Ornithine Decarboxylase (ODC) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ornithine Decarboxylase (ODC) Inhibitor The report ...
January 2022
60 pages
OX-40 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “OX-40 Agonist The report assesses the active OX-40 Agonist pipeline ...
January 2022
60 pages
P2X7 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “P2X7 Receptor Antagonist The report assesses ...
January 2022
60 pages
P2Y12 Platelet ADP Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “P2Y12 Platelet ADP Receptor Antagonist The report ...
January 2022
60 pages
Parathyroid Hormone Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Parathyroid Hormone Receptor Agonist The report ...
January 2022
60 pages
PDE Inhibitors - Pipeline Insight, 2022
US$ 2,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “PDE Inhibitor The report assesses the active PDE Inhibitor pipeline ...
January 2022
120 pages
PDE 1 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “PDE 1 Inhibitor The report assesses the active PDE 1 Inhibitor ...
January 2022
60 pages
PDE 10 inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “PDE 10 inhibitor The report assesses the active PDE 10 inhibitor ...
January 2022
60 pages
Penicillin-Binding Proteins (PBPs) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Penicillin-Binding Proteins (PBPs) Inhibitor The report ...
January 2022
60 pages
Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Peroxisome Proliferator-Activated Receptor (PPAR) Agonist The ...
January 2022
60 pages
Phosphoinositide 3-Kinase Beta (PI3K Beta) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Phosphoinositide 3-Kinase Beta (PI3K Beta) Inhibitor The ...
January 2022
60 pages
Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitor The ...
January 2022
60 pages
PI3K inhibitors - Pipeline Insight, 2022
US$ 2,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “PI3K Inhibitor The report assesses the active PI3K Inhibitor ...
January 2022
150 pages
PI3K/mTOR Pathway Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “PI3K/mTOR Pathway Inhibitor The report assesses ...
January 2022
60 pages
Pim Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Pim Kinase Inhibitor The report assesses the active Pim Kinase ...
January 2022
60 pages
Plasmin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Plasmin Inhibitor The report assesses the active Plasmin Inhibitor ...
January 2022
60 pages
